Fundraising FoxPappas Capital — Full Portfolio
108 tracked investments · listed companies and verified rows first
4DMT is a late-stage biotechnology company that develops gene delivery systems and genetic therapeutics targeting specific tissue types for various diseases.
BiotechHealthtechEmeryville, US
David Kirn(Chief Executive Officer, President, and Co-Founder)inDavid Schaffer(Director)inTheresa Janke(Chief of Staff, Co-Founder)in
BoardSharon Tetlow(Director)Margi McLoughlin(Director)
Co-investorsAmzak HealthBerkeley CatalystBOLD LongevityCasdin CapitalChiesi VenturesHercules Capital, Inc.+8 more
Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors.
BiotechHealthtechMedical DevicesBoston, US
Todd Foley(Co-founder and Chairman)inPatrick Baeuerle(Co-founder & Advisor)inShulamit Ron-Bigger(Executive Officer)inKyle D. Kuvalanka(Chief Financial Officer)inAkos Czibere(Chief Medical Officer)inPaul L. Feldman(Chief Scientific Officer)in
Co-investorsAndreessen HorowitzEcoR1 CapitalMPM BioImpactMRL Ventures FundRA CapitalTCG Crossover+5 more
Cyclerion is a biopharmaceutical company developing therapeutics for neuropsychiatric diseases, with a lead candidate (CYC-126) for treatment-resistant depression that pairs anesthetic agents with a personalized biofeedback-driven device.
BiotechDigital HealthMental HealthCambridge, US
William Huyett(Executive Officer)Mark G. Currie(Executive Officer)inRegina M. Graul(President and Chief Executive Officer)inOle Isacson(Director)Stephanie Lovell(Director)Marsha Fanucci(Director)
Co-investorsAberdare VenturesEcoR1 CapitalInvusPolaris Partners
Liquidia Technologies is a biopharmaceutical company that develops and commercializes drugs for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, including YUTREPIA, an inhaled dry-powder treprostinil formulation, and treprostinil injection through a profit-sharing arrangement with Sandoz, along with pipeline candidates based on its PRINT particle-engineering platform.
BiotechMorrisville, US
Kevin Gordon(President and Chief Financial Officer)Robert Lippe(Chief Operations Officer)Benjamin Maynor(Senior Vice President, Research and Development)Timothy Albury(Executive Officer)Neal F. Fowler(Chief Executive Officer)Roger A. Jeffs(Chief Executive Officer)in
Co-investorsCanaan Partners
Mirum Pharmaceuticals is a biopharmaceutical company that develops and delivers therapies for people living with rare diseases.
BiotechHealthtechSan Diego, US
Chris Peetz(Co-founder & Chief Executive Officer)inEric Bjerkholt(Executive Officer)inPeter Radovich(Executive Officer)in
BoardPatrick Heron(Director)inMichael Grey(Director)Timothy Walbert(Director)
Co-investorsChiesi VenturesFrazier Life SciencesLongitude CapitalMESA VERDE VENTURE PARTNERSNew Enterprise Associates (NEA)RiverVest Venture Partners+4 more
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule and antibody cancer therapies, including two FDA-approved medicines: revumenib (a menin inhibitor for acute leukemias) and axatilimab (a CSF-1R blocking antibody for graft-versus-host disease and fibrotic diseases), along with clinical-stage programs exploring expanded uses and combinations in oncology.
BiotechWaltham, US
John Pallies(Executive Officer)inArlene Morris(Executive Officer, Director)inMichael A. Metzger(Chief Executive Officer)inKeith A. Goldan(Chief Financial Officer)in
BoardDennis Podlesak(Director)inIvor Royston(Director)
Co-investorsAisling CapitalATEM Capital FundAvoro Capital AdvisorsBioBritDelos CapitalEcoR1 Capital+6 more
Achillion conducts research and development focused on addressing rare disease challenges through investigation of new therapeutic targets, modalities, and technologies.
BiotechHealthtech
Co-investorsConnecticut InnovationsSV Health InvestorsDomain Associates
Aer Therapeutics develops a science-driven therapeutic aimed at eliminating mucus plugs in the lungs to treat muco-obstructive lung diseases such as COPD and asthma.
BiotechHealthtechMedical DevicesRaleigh, US
Thomas Mathers(Executive Officer, Director)inJames Shaffer(Executive Officer, Director)John Fahy(Director)in
BoardChristy Shaffer(Director)inRishi Gupta(Director)inTim Shannon(Director)in
Co-investorsHatteras Venture PartnersOrbiMedCanaan Partners
BiotechSan Mateo, US
Anthony Ford(Executive Officer)inMichael Kitt(Executive Officer)inKathleen Sereda Glaub(Executive Officer, Director)in
BoardKevin Starr(Director)inArthur Pappas(Director)Liam Ratcliffe(Director)
Co-investorsDomain AssociatesFidelity InvestmentsJennison AssociatesThird Rock Ventures
Develops novel therapies for rare pediatric neurodegenerative diseases.
Co-investorsAsahi Kasei Corporate Venture CapitalLG Technology VenturesLifeSci Venture Partners
Developing a new class of antifungal medicine to overcome limitations of current therapies.
Co-investorsBioBritGolden SeedsKeiretsu ForumRiverVest Venture PartnersSofinnova Ventures3x5 Partners+4 more
Anthera produces makeup and skincare products made in France with natural, non-toxic ingredients that are cruelty-free and vegan.
ConsumerWellness & FitnessFrance, FR
Co-investorsSofinnova VenturesVantagePoint Capital Partners
BIO is the world's largest advocacy association representing biotechnology companies and research institutions across the United States and 30+ other nations.
BiotechEnterprise SoftwareSheridan, US
Casey Thomas(CEO)
Co-investorsBluepoint PartnersKorea Technology Finance Corporation
BioAtla develops novel monoclonal antibody and cell-based therapeutics for cancer treatment using proprietary platforms including Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!).
BiotechHealthtechMedical DevicesSan Diego, US
Jay M. Short(Executive Officer, Director)Richard A. Waldron(Executive Officer)inCarolyn Short(Director)
Co-investorsKeshif VenturesPfizer Venture InvestmentsHBM Healthcare InvestmentsPappas CapitalPfizer VenturesSoleus Capital
Molecular diagnostics company commercializing tools for diagnosing cardiovascular disease.
BiotechRedwood City, US
Mark Monane(Executive Officer)Gwen R. Carscadden(Executive Officer)David L. Levison(Executive Officer, Director)Deborah L. Kilpatrick(Executive Officer)inRobert F. Werner(Executive Officer)Douglas T. Ross(Executive Officer)
Co-investorsLongitude Capital
Chimerix is a biopharmaceutical company developing therapies for rare diseases and cancers, with a focus on advancing treatments through biomarker-driven approaches and precision medicine.
BiotechHealthtechMedical DevicesDurham, US
Mike Sherman(Chief Executive Officer and President)W. Garrett Nichols(Chief Medical Officer)Michael A. Alrutz(Executive Officer)Randall Lanier(Chief Science Officer)Roy W. Ware(Chief Manufacturing and Technology Officer)Heather Knight-Trent(Vice President of Regulatory Affairs)
Co-investorsAisling CapitalAlta PartnersAsset Management CompanyCanaan PartnersFrazier Life SciencesSanderling Ventures
CuraSen Therapeutics is a privately funded biopharmaceutical company developing treatments that selectively activate adrenergic receptors in the brain to restore noradrenergic signaling.
BiotechHealthtechSan Carlos, US
Anthony Ford(Executive Officer, Director)inBenjamin Potter(Executive Officer)Henry Skinner(Director)Liam Ratcliffe(Director)in
BoardRon Hunt(Director)inLoretta Tse, Ph.D.(Director)
Co-investorsAlta PartnersLongitude CapitalJohnson & Johnson Innovation – JJDCNew Leaf Venture PartnersPappas CapitalChiesi Ventures
Elitra develops yield infrastructure for onchain assets, allowing idle crypto holdings to be routed into yield-generating strategies.
FintechParis, FR
Anthony Hadwan(CEO)inSunil Thapa(CTO)in
Co-investorsEntrepreneur FirstTranspose Platform Management
Emerald BioAgriculture develops biology-based products and solutions using advanced biomanufacturing processes for plant, animal, and human health across various markets.
AgTechBiotechCleantechDeep TechHealthtechNew MaterialsKennett Square, US
Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets.
BiotechDeep TechSan Diego, US
Sergio Duron(Co-Founder & Chief Executive Officer)inSanford Madigan(Co-Founder, President & Chief Business Officer)inAnaleah Heidt(Chief Scientific Officer)in
BoardMarcos Milla(Director)inJay Lichter(Director)inTighe Reardon(Executive Officer)
Co-investorsFrazier Life SciencesLightspeed Venture PartnersSamsara BioCapitalAvalon BioVenturesPfizer Venture InvestmentsJ.P. Morgan Asset Management+1 more
Develops novel ocular therapies.
BiotechMorrisville, US
Ben Yerxa(Executive Officer)inEric Linsley(Executive Officer)in
BoardEd Mathers(Director)inStephen Bloch(Director)inSeth Rudnick(Director)inNeal Fowler(Director)
Co-investorsCanaan PartnersNew Enterprise Associates (NEA)+ND CapitalARCH Venture PartnersIllumina VenturesOMX Ventures
IlluminOss Medical makes a light-curable, patient-conforming intramedullary implant for minimally invasive fracture repair.
Co-investorsExcel Venture ManagementLongwood FundSlater Technology Fund
BiotechEast Providence, US
Manny Avila(Executive Officer, Director)inDirk Kuyper(Executive Officer, Director)inRobert Rabiner(Executive Officer)
BoardDaniel Omstead(Director)Fouad Azzam(Director)inRajeev Dadoo(Director)
Co-investorsEQT Life SciencesSR One Capital Management
Clinical-stage biotech developing immuno-oncology platforms for solid tumors including glioblastoma and melanoma.
BiotechMorrisville, US
Marc Banjak(Executive Officer)inMatthew W. Farber(Executive Officer)inWilliam G. Nichols(Executive Officer)Matthew R. Stober(Executive Officer, Director)
BoardRobert Bonczek(Director)Raymond Cheong(Director)
Kezar Life Sciences is a clinical-stage biotechnology company developing small-molecule therapeutics for immune-mediated diseases and cancer.
BiotechSouth San Francisco, US
John F. Fowler(Executive Officer, Director)inChristopher J. Kirk(Executive Officer, Director)
BoardDr. Gerald Chan(Director)Dr. Jean-Pierre Sommadossi(Director)
Co-investorsBay City CapitalChiesi VenturesQiming Venture Partners USASolasta VenturesCowen Healthcare InvestmentsEcoR1 Capital+1 more
LEAD.Bot is a Microsoft Teams bot that automatically matches employees within an organization for virtual meetings and mentorship programs.
Future of WorkHR TechSaaS
Yumi Kimura(Co-founder & CEO)in
Co-investorsExpert DOJONewfund CapitalOridun Capital ManagementKleiner PerkinsLightspeed Venture PartnersSaga Ventures+3 more
Acquired by Shire in 2014 (now part of Takeda).
BiotechMedical DevicesDurham, US
John McKearn(Director)Edward E. Greene(Director)Rosina Maar Pavia(Director)Ford S. Worthy(Executive Officer)Michael Grey(Executive Officer, Director)
Co-investorsFrazier Life SciencesLongitude CapitalOberland CapitalRiverVest Venture PartnersSanofi Ventures
Milestone Pharmaceuticals is a life sciences company that develops therapies for patients with cardiovascular and other diseases.
BiotechDigital HealthHealthtechMedical DevicesMontreal, US
Ela Borenstein(Director)Francis Plat(Executive Officer)Yves Rosconi(Director)Scott Weiner(Director)Martin Maguire(Executive Officer)Philippe Douville(Executive Officer, Director)
Co-investorsAmplitude Venture CapitalDomain AssociatesForbionRTW Investments L.P.
Mirati develops investigational medicines and treatments for patients with multiple myeloma and other oncology indications.
BiotechHealthtechMedical Devices
Co-investorsAvoro Capital AdvisorsBioBritBoxer Capital, LLCNextech Invest
NuVasive provides intraoperative neuromonitoring (IONM) services and implantable orthopedic and spinal devices for hospitals, surgeons, and patients, supported by board-certified neurologists and neurophysiologists.
HealthtechMedical Devices
James Marino, MD(Founder)in
Co-investorsDuke Capital Partners
Xoilac TV is a free online football (soccer) live-streaming platform serving fans in Vietnam, offering Full HD match broadcasts of European, Asian, Vietnamese, and international competitions.
ConsumerMedia & EntertainmentSports Tech
Co-investorsAisling CapitalChiesi VenturesNew Enterprise Associates (NEA)RiverVest Venture PartnersAbingworthAmzak Health+3 more
BiotechGreenville, US
Kevin Weeks(Executive Officer, Director)Katherine Warner(Executive Officer)Joshua Resnick(Director)Michael Solomon(Director)John Gustofson(Director)
BoardMike Dial(Director)in
Co-investorsHatteras Venture PartnersIllumina VenturesM VenturesMC Healthcare VenturesSV Health InvestorsAbbVie+2 more
HealthtechPlymouth, US
Thomas Westling(Executive Officer, Director)inMartha Shadan(Executive Officer, Director)Randy Nuernberg(Executive Officer)Craig Van Kampen(Executive Officer)
BoardFouad Azzam(Director)inScott Weiner(Director)in
Co-investorsNew Enterprise Associates (NEA)EQT Life SciencesPappas Capital
GSK is a biopharmaceutical company that discovers, develops, and delivers medicines and vaccines for patients.
BiotechHealthtechLondon, GB
Mary Lynne Hedley(Executive Officer, Director)Leon O. Moulder, Jr.(Executive Officer, Director)Jeffrey Hanke(Executive Officer)Joseph L. Farmer(Executive Officer)inGrant C. Bogle(Executive Officer)Martin H. Huber(Executive Officer)
Co-investorsColorado BioScience AssociationKleiner PerkinsNew Enterprise Associates (NEA)Ridgeback CapitalAvoro Capital Advisors
Tune Therapeutics develops a therapeutic platform targeting the epigenome to treat complex diseases and regenerative medicine applications.
BiotechDeep TechHealthtechLongevityMedical DevicesDurham and Seattle, US
Akira Matsuno(Co-Founder, President, CFO, COO)inDerek Jantz(Executive Officer)inCharles Gersbach(Co-Founder)inJohn McHutchison(CEO, Chairman of the Board)inDan McHugh(Co-Founder, Investor)inBlythe Sather(Executive Officer)in
Co-investorsDuke Capital PartnersHatteras Venture PartnersMission BiocapitalNew Enterprise Associates (NEA)RV Invest GmbHSaisei Ventures+2 more
Ultragenyx is a biotechnology company focused on developing treatments for patients living with rare genetic diseases.
BiotechHealthtechMedical Devices
Co-investorsColorado BioScience AssociationF-Prime CapitalSanofi Ventures
A biopharmaceutical company developing medicines and vaccines with a focus on clinical research and development for human health.
BiotechSan Diego, US
David Johnson(Executive Officer, Director)Cam Gallagher(Director)Scott L. Glenn(Director)in
Co-investorsChiesi VenturesDecheng CapitalSofinnova VenturesVedanta CapitalViking GlobalArix Bioscience+4 more
Developing novel treatments based on the 12-LOX pathway for immuno-inflammatory diseases.
Co-investorsAlumni VenturesHatteras Venture PartnersSanofi VenturesAlexandriaGenesys CapitalJDRF T1D Fund+4 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
106784DMTAchillionAclara BiosciencesAfferentAmplyx PharmaceuticalsAnthera PharmaAnthera PharmaceuticalsArenaArena PharmaceuticalsArgomedAthersysBalance TherapeuticsBarosenseBayhill TherapeuticsBioAesthetics:BiosyntechBraincellsCalyx TherapeuticsCeNeRxCenerx BiopharmaCequent PharmaceuticalsCerexaCognetixCoLucidCoLucid PharmaceuticalsCurisCurzion PharmaceuticalsDynogen PharmaceuticalsEbm SolutionsElitra PhramaceuticalsEmeraldEnlazaFlowcardiaGentisLead TherapeuticsLipoScienceLumenaMarinaMarina BiotechMethylgeneMiratiMirumNereusOptherionOrphoMedPanacosPanacos PharmaceuticalsPeninsula PharmaceuticalsPlexigenPlexxikonReprogenesisSelventaSensysSensys MedicalSignaseSolu TherapeuticsSorrisoSphericsSungarddxSyntonixSyntonix PharmaceuticalsTargegenThrasosThrasos TherapeuticsTyrxUltragenyx PharmaceuticalVariagenicsX Ceptor TherapeuticsX-Ceptor
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.